Cartesian Q2 2026: Cash Runway to 2028, Phase 3 AURORA Trial Fuels R&D Growth
RNAC sits 48% above its 52-week low of $5.6.
Summary
Cartesian Therapeutics reported Q2 2026 earnings with a non-cash gain driving net income, but the key takeaway is a cash runway into 2028, supported by $149.3M in cash and a $50M loan draw. R&D spending surged for the pivotal Phase 3 AURORA trial.
Key Events · Earnings and Guidance · RNAC
-
Cash Runway Extended into 2028
With $149.3 million in cash and equivalents as of June 30, 2026, plus a $50 million loan draw, operations are funded into 2028, eliminating near-term liquidity risk.
-
Phase 3 AURORA Trial Drives R&D Surge
R&D expenses rose 37% year-over-year to $20.4 million, primarily for the ongoing Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, the company's lead asset.
-
Non-Cash Gain Masks Operating Loss
Reported net income of $15.8 million was entirely due to a $49.2 million non-cash gain from revaluing the CVR liability; the operating loss was $29.2 million.
-
New WestGene Licensing Deal for In Vivo CAR-T
A licensing agreement with WestGene Biopharma for in vivo CAR-T therapies was entered, with $0.8 million in R&D expense recognized in Q2.
Analysis · RNAC · Life Sciences
Cartesian's Q2 2026 net income of $15.8 million was entirely driven by a non-cash $49.2 million gain from revaluing its contingent value rights liability—not from operations. The more critical development is the cash position: $149.3 million on hand, which extends the runway into 2028 and removes near-term liquidity concerns. R&D expenses jumped 37% to $20.4 million, reflecting the ramp-up of the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, the company's lead asset. A new licensing deal with WestGene adds an early-stage in vivo CAR-T program. Financing activities included $19.3 million raised through the ATM and a $50 million draw on the K2 HealthVentures loan facility, though the embedded derivative on that loan created a $4.5 million non-cash loss. The balance sheet remains heavily burdened by a $356.7 million CVR liability, but that is funded solely by Sobi milestone payments, not Cartesian's own cash.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.3% of the 1681 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAC was trading at $8.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $245.3M. The 52-week trading range was $5.60 to $12.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.